Psoriatic Arthritis

A 20 mg weekly oral dose of methotrexate shows potential as a low-cost treatment for reducing pain and stiffness in patients with symptomatic hand osteoarthritis, according to the results of the METHODS trial.

Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.

Results demonstrated a low persistence rate for apremilast among patients with PsA, highlighting a notable barrier to treatment success.

Achievement of minimal disease activity and remission were observed in approximately half of patients with psoriatic arthritis receiving upadacitinib.

The approval of the intravenous formulation of secukinumab allows healthcare providers to better tailor treatment to their patients’ unique needs. 

While the results showed a high prevalence of suspected musculoskeletal symptoms in patients with psoriasis, only a small number were due to psoriatic arthritis.

Hematologic malignancy was not affected by the type of biologics prescribed, treatment patterns, comedications, comorbidities, or cumulative defined daily doses.

Patients with psoriatic disease have a significantly higher risk of developing a variety of autoimmune diseases, as indicated by the Charlson Comorbidity Index.

Self-injection of bimekizumab was generally well tolerated among patients with psoriatic arthritis.

This decision by the FDA could offer psoriatic arthritis patients a dosing regimen each month that does not require pre-mediation or regular lab assessments.

Retention rates for golimumab treatment at the 5-year mark were consistently high when used as a first-line therapy and did not significantly differ across conditions.

Investigators found intestinal permeability and fecal and plasma metabolomic profiles of patients with PsA in the FLORA trial cohort were associated with clinical response to FMT.

Patients with SARS-CoV-2 infection experienced a 22% increase in the incidence of immune-mediated inflammatory diseases, including T1DM, IBD, and psoriasis.

Most patients were able to achieve clear or almost clear skin, and improvement of arthritis and difficult-to-treat areas, with guselkumab and risankizumab treatment.

Of the 333 patients with PsA and 457 patients with axSpA, there were 1.09 serious infections per 100 patient years (95% CI .85 – 1.35).

Patients diagnosed with psoriatic arthritis and obesity were older, more frequently women, had worse pain, physical function, and health-related quality of life, and had higher tender joint and enthesitis counts when compared with nonobese patients.

Of the 130 patients with psoriatic arthritis who participated in a telemedicine assessment, 83% were happy with the consultation.

A recent study found initial monotherapy for chronic inflammatory arthritis yields better treatment persistence and safety relative to combination therapy.

At week 52, patients in the bimekizumab cohort demonstrated sustained clinical responses, which were consistent with results reported at week 16.

A study on juvenile idiopathic arthritis emphasizes early initiation of biologic treatment for better long-term outcomes, as delayed treatment is linked to greater physical disability and worse quality of life in adulthood.

High-intensity interval training appears safe for individuals with psoriatic arthritis, as a study found no significant increase in inflammation assessed by ultrasound and MRI.

In patients receiving guselkumab, achieving NAPSI 0/1 at week 24 and week 48 was associated with lower baseline NAPSI and week 16 PASI.

In this Q&A, Vinod Chandran, MBBS, MD, DM, PhD, discussed a method to analyze biomarkers that may differentiate patients with psoriasis and psoriatic arthritis.

This retrospective study from Japan highlighted several key elements linked to a generalized pustular psoriasis diagnosis among individuals with psoriasis vulgaris.

This small study found DNA methylation profiles in CD4+ T-cells may represent a stable and reliable biomarker.

Significantly greater improvements in back pain and morning stiffness were observed in patients receiving ixekizumab compared with placebo.

Continued reductions in serum acute phase proteins and collagen degradation proteins observed in patients with psoriatic arthritis receiving guselkumab may be linked to sustained symptom improvements.

An interim analysis from the UPJOINT trial provides insight into the effects of upadacitinib use in real-world settings among patients with oligo- or polyarticular psoriatic arthritis.

Investigators believe a more consistent application of disease activity measures may help to guide treatment decisions and improve quality of care.

A higher number of patients receiving guselkumab treatment reported ≥1 improvement as early as week 4, which continued to improve through week 24.